PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotype

Abstract

PTEN is a tumour suppressor frequently mutated in many types of cancers. Here we show that targeted disruption of PTEN leads to neoplastic transformation of human neural stem cells (NSCs), but not mesenchymal stem cells. PTEN-deficient NSCs display neoplasm-associated metabolic and gene expression profiles and generate intracranial tumours in immunodeficient mice. PTEN is localized to the nucleus in NSCs, binds to the PAX7 promoter through association with cAMP responsive element binding protein 1 (CREB)/CREB binding protein (CBP) and inhibits PAX7 transcription. PTEN deficiency leads to the upregulation of PAX7, which in turn promotes oncogenic transformation of NSCs and instates ‘aggressiveness' in human glioblastoma stem cells. In a large clinical database, we find increased PAX7 levels in PTEN-deficient glioblastoma. Furthermore, we identify that mitomycin C selectively triggers apoptosis in NSCs with PTEN deficiency. Together, we uncover a potential mechanism of how PTEN safeguards NSCs, and establish a cellular platform to identify factors involved in NSC transformation, potentially permitting personalized treatment of glioblastoma.

Metformin alleviates human cellular aging by upregulating the endoplasmic reticulum glutathione peroxidase 7

“…Firefly luciferase activity was normalized to renilla luciferase activity for each transfected cell sample. The specific procedure was performed according to a published paper (Duan et al., 2015). …”

Li–Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53

“…Already, this approach has shown promise in other genes. Engineered human embryonic stem cell (ESC)-derived neural progenitor cells (NPCs) and neural stem cells (NSCs) have been used to study and model diffuse intrinsic pontine gliomas (DIPGs) [196] and GBM [197] respectively. Both of these studies identified novel potential drugs for brain tumors.…”

Modeling Cancer with Pluripotent Stem Cells

“…Several groups have applied patient-derived iPSCs and/or engineered PSCs to phenocopy cancer features, explore disease mechanisms and screen potential therapeutic drugs [30–34]. Their experience highlights the potential of human PSCs in cancer studies by overcoming limitations related to availability of patient samples or translation of results from animal models or cell lines with inappropriate genetic backgrounds.…”

“…While GBMs are genetically very diverse, mutations in PTEN are common and correlate with increased invasion, drug resistance and tumor recurrence [41]. Duan et al engineered PTEN-deficient ESCs using a TALEN-based genome editing methodology and derived neural stem cells (NSCs) to model GBM [34]. PTEN-deficient NSCs displayed the GBM-associated gene signature and formed intracranial tumors in vivo .…”

“…PSC differentiation protocols have been established for generation of hepatic cells [42–44], intestinal tissue [45], thyroid follicular cells [46], airway epithelial cells [47–49], renal progenitor cells [50, 51], retinal cells [52–55], epithelial stem cells [56], epidermal keratinocytes [57], myeloid cells [58, 59], neurons [34, 60], MSCs [61], and melanocytes [62], among many others. Application of these protocols to cancer patient-derived iPSCs and engineered ESCs should allow research of cancers of these organs.…”